Literature DB >> 2447809

Eosinophil cationic protein and myeloperoxidase in nasal secretion as markers of inflammation in allergic rhinitis.

A Linder1, P Venge, H Deuschl.   

Abstract

The inflammatory component of allergic rhinitis was studied by measuring the concentration and content of eosinophil cationic protein (ECP, specific for eosinophils) and myeloperoxidase (MPO, specific for neutrophils) in samples of nasal secretion from 20 pollen-allergic subjects. All secretion samples contained measurable concentrations of both proteins. The mean ECP concentrations on two occasions without pollen exposure were 950 and 1170 micrograms/l. The ECP concentration during the pollen season without any therapy (mean 1160 micrograms/l) did not differ significantly from the baseline values, but intranasal corticosteroid therapy resulted in a significant decrease (mean 530 micrograms/l). The concentration of MPO was about 10 times higher than that of ECP, but the changes in MPO were nonsignificant throughout the observation period. An inverse correlation was found between the threshold dose in histamine challenges and the ECP level expressed either as concentration or as content. Furthermore, the ECP concentration and content 1 day after a positive allergen challenge were both significantly correlated with the strength of the challenge reaction. Measurements of ECP in nasal secretions are useful for studying the presence and activity of eosinophils in the nasal mucosa, and may prove of value in clinical investigations on patients with allergic rhinitis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447809     DOI: 10.1111/j.1398-9995.1987.tb00388.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  7 in total

Review 1.  Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies.

Authors:  G W Canonica; E Compalati
Journal:  Clin Exp Immunol       Date:  2009-08-25       Impact factor: 4.330

2.  The effect of platelet-activating factor on the responsiveness of the human nasal airway.

Authors:  C E Austin; J C Foreman
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

Review 3.  Hyperresponsiveness in the human nasal airway: new targets for the treatment of allergic airway disease.

Authors:  P J Turner; J C Foreman
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

4.  Diagnostic Value of a Novel Eosinophil Cationic Protein-Myeloperoxidase Test Paper Before and After Treatment for Allergic Rhinitis.

Authors:  Yang Xi; Yu-Qin Deng; Han-Da Li; Wo-Er Jiao; Jin Chen; Jian-Jun Chen; Ze-Zhang Tao
Journal:  J Asthma Allergy       Date:  2022-08-04

5.  Tumour necrosis factor-alpha in nasal allergy.

Authors:  K Hisamatsu; T Ganbo; T Nakazawa; T Nakajima; J Ko; R Goto; Y Murakami; K Misui
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

6.  Elevation of soluble interleukin-2 receptor levels in nasal allergy.

Authors:  K Hisamatsu; T Ganbo; T Nakazawa; S Horiguchi; S Shimomura; Y Murakami
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

7.  Nasal mucus proteome and its involvement in allergic rhinitis.

Authors:  Peter Valentin Tomazic; Barbara Darnhofer; Ruth Birner-Gruenberger
Journal:  Expert Rev Proteomics       Date:  2020-04-08       Impact factor: 3.940

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.